<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006473</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02363</org_study_id>
    <secondary_id>ID99-406</secondary_id>
    <secondary_id>CDR0000068297</secondary_id>
    <nct_id>NCT00006473</nct_id>
  </id_info>
  <brief_title>Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of oxaliplatin in treating patients who have&#xD;
      relapsed or refractory non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways&#xD;
      to stop tumor cells from dividing so they stop growing or die&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate to oxaliplatin in patients with relapsed or refractory&#xD;
      non-Hodgkin's lymphoma.&#xD;
&#xD;
      II. Determine the treatment-related toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to histologic subtype&#xD;
      (indolent vs aggressive).&#xD;
&#xD;
      Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a&#xD;
      maximum of 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 72 patients will be accrued for this study within 2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Using a Simon's two-stage model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Analyzed using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (oxaliplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (oxaliplatin)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed recurrent or refractory non-Hodgkin's&#xD;
             lymphoma (NHL) of any histologic subtype&#xD;
&#xD;
               -  Indolent&#xD;
&#xD;
                    -  Follicular small cleaved cell&#xD;
&#xD;
                    -  Follicular mixed cell&#xD;
&#xD;
                    -  Small lymphocytic&#xD;
&#xD;
                    -  Mucosa-associated lymphoid tissue (MALT)&#xD;
&#xD;
                    -  Monocytoid B-cell&#xD;
&#xD;
                    -  Waldenstrom's macroglobulinemia&#xD;
&#xD;
               -  Aggressive&#xD;
&#xD;
                    -  Follicular large cell&#xD;
&#xD;
                    -  Diffuse large cell&#xD;
&#xD;
                    -  Immunoblastic&#xD;
&#xD;
                    -  Mantle cell&#xD;
&#xD;
                    -  Ki-1+ NHL&#xD;
&#xD;
                    -  Peripheral T-cell&#xD;
&#xD;
                    -  Angiocentric and angioimmunoblastic&#xD;
&#xD;
                    -  Transformed lymphoma&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
          -  No more than 3 prior treatment regimens as follows:&#xD;
&#xD;
               -  Primary radiotherapy is 1 regimen&#xD;
&#xD;
               -  Combined therapy with radiotherapy and chemotherapy is 1 regimen&#xD;
&#xD;
               -  Alternating therapy is 1 regimen&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100%&#xD;
&#xD;
          -  WBC count at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT/SGPT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No neuropathy greater than grade 1&#xD;
&#xD;
          -  No history of allergy to platinum compounds or antiemetics&#xD;
&#xD;
          -  No uncontrolled illness&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No concurrent colony-stimulating factors during first course of therapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anas Younes</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

